By Dr. Asnat Raziel, bariatric surgeon specializing in obesity treatment, metabolic health and healthy longevity; Director of the Multidisciplinary Center for Obesity Treatment, Assia Medical, Assuta Ramat HaChayal, Tel Aviv
Rybelsus pill: semaglutide in a daily tablet
The Rybelsus pill contains semaglutide, the same active ingredient found in Ozempic and Wegovy. The difference is how you take it: one tablet in the morning instead of a weekly injection. Regulators approved the drug for the treatment of type 2 diabetes. In addition, since 2025 US regulators have also approved it to reduce the risk of cardiovascular events in people with diabetes at high risk.
That makes Rybelsus especially appealing to people who are wary of injections. However, you have to take it in a very specific way. In this article, you’ll find what the drug does, what the studies showed, how to take it and who it is suitable for.
How the Rybelsus pill differs from semaglutide injections
Semaglutide is a small protein, and the stomach breaks down proteins quickly. For this reason, to help it reach the bloodstream, the tablet contains an absorption enhancer called SNAC (salcaprozate sodium). In effect, SNAC protects the drug in the stomach and helps it pass through the stomach wall.
In practice, the body absorbs only a small fraction of each dose. That’s why tablet doses are much higher than injection doses. For example, Ozempic comes as an injection of up to 2 mg per week, whereas Rybelsus comes as a daily tablet of several milligrams.
How the Rybelsus pill works
Rybelsus belongs to the GLP-1 receptor agonist family. GLP-1 is a hormone the gut releases after a meal. The drug mimics its action, and as a result it:
- Boosts insulin release only when blood sugar is high
- Reduces the release of glucagon, a hormone that raises blood sugar
- Slows stomach emptying
- Acts on the hunger and satiety centers in the brain
- Quiets “food noise,” those intrusive thoughts about food
As a result, blood sugar levels fall, appetite decreases and weight comes down gradually. For this reason, the drug can also help patients who struggle with emotional eating or constant hunger.
What the PIONEER trials showed
The PIONEER trial program tested Rybelsus in thousands of patients with type 2 diabetes. For example, the PIONEER 2 and PIONEER 4 trials compared it with standard diabetes medications:
- Vs. empagliflozin (Jardiance): After 26 weeks, HbA1c fell by 1.4% with Rybelsus, compared with 0.9% with Jardiance.
- Weight in the same trial: After 52 weeks, patients had lost 4.7 kg, compared with 3.8 kg.
- Vs. liraglutide (Victoza): After 52 weeks, patients had lost 5.0 kg, compared with 3.1 kg on Victoza and 1.2 kg on placebo.
HbA1c reflects average blood sugar over the past three months. A drop of 1% or more is highly significant clinically.
The Rybelsus pill and the heart: the SOUL trial
For years, doctors waited for cardiovascular data on the tablet. The answer came in 2025 with the SOUL trial. The trial enrolled 9,650 patients aged 50 and over with type 2 diabetes, all of whom also had cardiovascular disease, chronic kidney disease or both.
Patients received Rybelsus up to 14 mg a day or placebo, on top of their usual treatment. Overall, average follow-up was about four years. The results:
- A major cardiovascular event occurred in 12.0% of patients on Rybelsus, compared with 13.8% on placebo.
- In other words, the risk fell by 14% (hazard ratio 0.86; 95% confidence interval 0.77 to 0.96).
- Gastrointestinal side effects occurred in 5.0% versus 4.4%.
Following the trial, the US Food and Drug Administration (FDA) approved a new indication in October 2025. In the US, Rybelsus is now approved to reduce the risk of heart attack, stroke and cardiovascular death in people with diabetes at high risk. Moreover, the indication also includes patients who have not yet had a cardiovascular event.
Is the Rybelsus pill approved for weight loss?
No. Rybelsus is approved for type 2 diabetes only. Even so, weight loss is a common result of treatment. In the trials, it averaged about 4 to 5 kg over a year.
For dedicated obesity treatment, there is now a different semaglutide tablet at a 25 mg dose. This is the Wegovy pill, which achieves much greater weight loss. I explain the differences between the two in my article on Rybelsus vs. the Wegovy pill.
How to take the pill correctly
Absorption of the tablet is very sensitive, so taking it incorrectly can reduce its effectiveness. It’s important to follow these rules:
- Take it in the morning, on an empty stomach, right after you wake up.
- Swallow it with only a little water, up to about 120 ml. Not with coffee, tea or juice.
- Wait at least 30 minutes before eating, drinking or taking other medications.
- Swallow the tablet whole, without splitting, crushing or chewing it.
- Missed a dose? Skip it and continue as usual the next day.
Rybelsus pill doses: old and new
In recent years, the manufacturer has replaced the tablet with a new formulation. Because the body absorbs the new formulation better, its doses in mg are lower:
- The original formulation: 3 mg, 7 mg and 14 mg.
- The new formulation: 1.5 mg, 4 mg and 9 mg.
According to the dosing guidelines, treatment starts at 1.5 mg a day for 30 days, then moves to 4 mg a day. If you need better blood sugar control, the dose goes up to 9 mg after another 30 days. In the original formulation, the corresponding steps are 3, 7 and 14 mg.
Note: you cannot swap the two formulations milligram for milligram. For example, 4 mg of the new formulation is equivalent to 7 mg of the old one, and 9 mg is equivalent to 14 mg. Therefore, make any switch between formulations only under the guidance of a doctor and pharmacist. In Israel, check with your pharmacist which formulation you are receiving.
Side effects and safety
The side effects are similar to those of injectable semaglutide. The most common are:
- Nausea and a feeling of fullness
- Reduced appetite
- Diarrhea or constipation
- Gas and abdominal discomfort
Most are mild and pass within a few weeks, especially when the dose goes up gradually. There are also practical ways to ease side effects, such as eating small meals and avoiding fatty foods.
Rare risks include pancreatitis, gallstones, temporary worsening of diabetic retinopathy and kidney damage due to dehydration. In addition, the risk of low blood sugar rises when patients combine the drug with insulin or a sulfonylurea.
Who should not take the pill
Anyone with a personal or family history of medullary thyroid cancer or MEN 2 syndrome should not take Rybelsus. People with hypersensitivity to semaglutide are not suitable for treatment either. In addition, women should not take the drug during pregnancy or breastfeeding.
The advantages of the Rybelsus pill
- Taken by mouth: a good solution for people who are wary of injections.
- No pen, no refrigeration and no injection training.
- Fast blood sugar control: improvement within the first few weeks.
- Heart protection: a proven risk reduction in the SOUL trial.
- Moderate weight loss as a welcome side benefit.
On the other hand, the tablet requires daily discipline, and the weight loss is more modest than with injections at obesity doses.
A holistic approach: the drug as part of a program
Rybelsus alone does not address the causes of diabetes and excess weight. The best results come from combining it with:
- Personalized nutritional counseling
- Regular physical activity, including strength training
- Behavioral therapy and work on eating patterns
- Good sleep and stress management
- Close medical follow-up
In fact, patients who stay in a multidisciplinary program achieve more stable results over time. For more information, read my guide to obesity and type 2 diabetes.
Frequently asked questions about the Rybelsus pill
Is Rybelsus “Ozempic in a pill”?
Yes, in the sense that the active ingredient is the same. However, the doses, the way you take it and the approved indications are different.
Can I take the pill with coffee?
No. Take it with only a little water, and wait half an hour before your coffee.
What is the difference between Rybelsus and the Wegovy pill?
Rybelsus treats diabetes, at doses of up to 14 mg in the original formulation. By contrast, the Wegovy pill treats obesity, at a dose of 25 mg.
Can I switch from an injection to the tablet?
Sometimes, depending on the indication and your response to treatment. You make the decision together with your doctor.
What happens when you stop treatment?
Blood sugar levels usually rise again, and weight also tends to return. That’s why this is usually a long-term treatment.
The bottom line
The Rybelsus pill brought semaglutide into a daily tablet. It improves blood sugar control, leads to modest weight loss and reduces the risk of cardiovascular events in people with diabetes at high risk. On the other hand, you must take it carefully, in the morning, on an empty stomach. So always make decisions about treatment, dose and formulation with a doctor.
The information in this article is general and does not replace personalized medical advice.
References
Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes
Novo Nordisk, the drug’s manufacturer, funded the SOUL and PIONEER trials.
